Establishment of a highly differentiated thyroid cancer cell line of Hürthle cell origin.
Hürthle cell carcinomas (HCC) of the thyroid are a variant of follicular thyroid tumors. In contrast to follicular thyroid carcinoma, HCC rarely take up radioiodine and frequently metastasize to the lymph nodes. Histologically they are indistinguishable from Hürthle cell adenomas except for evidence of invasion and metastasis. How these carcinomas develop and why they behave differently than other follicular tumors is not known. Although some differentiated thyroid cancer cell lines exist, none are from Hürthle cell tumors. We have established a well-differentiated thyroid cancer cell line from a metastasis of a HCC, designated XTC.UC1. In vitro, XTC cells display epitheloid morphology, grow with a population doubling time of 4.3 +/- 0.3 days, migrate, and invade through reconstituted basement membranes. The cells are immunoreactive for and release thyroglobulin, respond to thyrotropin (TSH) with increase of intracellular cyclic adenosine monophosphate (cAMP), proliferation, and invasion of reconstituted basement membrane, thus exhibiting characteristics of well-differentiated thyroid carcinoma. In vivo, xenografted XTC cells grow with a doubling time of 9.8 +/- 0.8 days. Tumors spontaneously metastasize to the lymph nodes and less frequently to the lungs and the liver. The cells retained their differentiated function in vivo as assessed by human thyroglobulin (hTG) secretion and immunohistochemistry. This is a first report of the establishment of a unique, highly differentiated thyroid carcinoma cell line derived from an HCC. Based on the ability to invade through reconstituted basement membrane in vitro and the potential to metastasize in vivo, this cell line may provide a unique model to study invasion and metastazation of well-differentiated thyroid cancer.
Zielke
A
A
Department of Surgery, Philipps-University of Marburg, Germany.
Tezelman
S
S
Jossart
G H
GH
Wong
M
M
Siperstein
A E
AE
Duh
Q Y
QY
Clark
O H
OH
D000230:Adenocarcinoma / Q000378:metabolism / Q000473:pathology* / Q000556:secondary; D015197:Carcinogenicity Tests; D002455:Cell Division / Q000187:drug effects; D002465:Cell Movement / Q000502:physiology; D000242:Cyclic AMP / Q000378:metabolism; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D007425:Intracellular Membranes / Q000378:metabolism; D007621:Karyotyping; D008875:Middle Aged; D009361:Neoplasm Invasiveness / Q000473:pathology; D013954:Thyroglobulin / Q000378:metabolism; D013964:Thyroid Neoplasms / Q000378:metabolism / Q000473:pathology*; D013972:Thyrotropin / Q000494:pharmacology; D014407:Tumor Cells, Cultured
D013972:Thyrotropin; D013954:Thyroglobulin; D000242:Cyclic AMP